| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3269774 | HPB | 2011 | 6 Pages |
Abstract
Percutaneous transhepatic IAT is feasible and safe. Islet infusion in the immediate postoperative period is cost-effective. Further follow-up is needed to assess longterm results.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Katherine A. Morgan, Michael Nishimura, Renan Uflacker, David B. Adams,